BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36434947)

  • 41. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
    Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
    Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does the Increased Rate of Serous Component (≤25% vs. >25%) Increase Recurrence in Endometrial Cancer With Serous Plus Endometrioid Histology?
    Kaban A; Topuz S; Sozen H; Salihoglu Y
    J Obstet Gynaecol Can; 2019 Feb; 41(2):160-165. PubMed ID: 30316715
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic factors determining survival after extrapelvic recurrence in endometrioid type endometrial cancer.
    Kilic F; Unsal M; Cakir C; Yuksel D; Kilic C; Dur R; Kimyon Comert G; Turan T; Turkmen O
    Taiwan J Obstet Gynecol; 2021 Nov; 60(6):1023-1030. PubMed ID: 34794732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survival outcomes of women with grade 3 endometrioid endometrial cancer: the impact of adjuvant treatment strategies.
    Gungorduk K; Muallem J; Aşıcıoğlu O; Gülseren V; Güleç ÜK; Meydanlı MM; Sehouli J; Özdemir A; Şahin H; Khatib G; Miranda A; Boran N; Şenol T; Yıldırım N; Turan T; Oge T; Taşkın S; Vardar MA; Ayhan A; Muallem MZ
    Arch Gynecol Obstet; 2022 Mar; 305(3):671-681. PubMed ID: 34448946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
    Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
    Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumour-free distance from serosa is a better prognostic indicator than depth of invasion and percentage myometrial invasion in endometrioid endometrial cancer.
    Chattopadhyay S; Galaal KA; Patel A; Fisher A; Nayar A; Cross P; Naik R
    BJOG; 2012 Sep; 119(10):1162-70. PubMed ID: 22804815
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer.
    Han KH; Park NH; Kim HS; Chung HH; Kim JW; Song YS
    Gynecol Oncol; 2014 Aug; 134(2):293-6. PubMed ID: 24854062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
    Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
    Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwan.
    Lai YL; Chang CS; Chang K; Kim HS; Chen J; Cheng WF; Chen YL; Lee YY
    Gynecol Oncol; 2022 Oct; 167(1):65-72. PubMed ID: 35995599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does tumor size have prognostic value in patients undergoing lymphadenectomy in endometrioid-type endometrial cancer confined to the uterine corpus?
    Çakır C; Kılıç İÇ; Yüksel D; Karyal YA; Üreyen I; Boyraz G; Durmuş Y; Gültekin M; Özgül N; Karalök MA; Salman MC; Yüce K; Turan AT
    Turk J Med Sci; 2019 Oct; 49(5):1403-1410. PubMed ID: 31650820
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors related to recurrence in non-obese women with endometrial endometrioid adenocarcinoma.
    Panggid K; Cheewakriangkrai C; Khunamornpong S; Siriaunkgul S
    J Obstet Gynaecol Res; 2010 Oct; 36(5):1044-8. PubMed ID: 21058438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer.
    AlHilli MM; Mariani A; Bakkum-Gamez JN; Dowdy SC; Weaver AL; Peethambaram PP; Keeney GL; Cliby WA; Podratz KC
    Gynecol Oncol; 2014 Jun; 133(3):485-93. PubMed ID: 24690476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study.
    Ayhan A; Topfedaisi Ozkan N; Öz M; Kimyon Comert G; Firat Cuylan Z; Çoban G; Turkmen O; Erdem B; Şahin H; Akbayır Ö; Dede M; Turan AT; Celik H; Güngör T; Haberal A; Arvas M; Meydanli MM
    J Gynecol Oncol; 2018 Jul; 29(4):e48. PubMed ID: 29770619
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy.
    Bakkum-Gamez JN; Mariani A; Dowdy SC; Weaver AL; McGree ME; Martin JR; Keeney GL; Jatoi A; Gostout BS; Podratz KC
    Gynecol Oncol; 2014 Mar; 132(3):578-84. PubMed ID: 24434057
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor size: a better independent predictor of distant failure and death than depth of myometrial invasion in International Federation of Gynecology and Obstetrics stage I endometrioid endometrial cancer.
    Chattopadhyay S; Cross P; Nayar A; Galaal K; Naik R
    Int J Gynecol Cancer; 2013 May; 23(4):690-7. PubMed ID: 23518862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study.
    Elshaikh MA; Al-Wahab Z; Mahdi H; Albuquerque K; Mahan M; Kehoe SM; Ali-Fehmi R; Rose PG; Munkarah AR
    Gynecol Oncol; 2015 Feb; 136(2):235-9. PubMed ID: 25511158
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adjuvant Chemotherapy versus Radiotherapy in High-risk, Early-stage Endometrioid Endometrial Carcinoma.
    Wu M; Yang YN; Huang YH; Cai J; He XQ; Wang ZH
    Curr Med Sci; 2022 Feb; 42(1):185-191. PubMed ID: 34669113
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
    Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study.
    Ghoniem K; Larish AM; Dinoi G; Zhou XC; Alhilli M; Wallace S; Wohlmuth C; Baiocchi G; Tokgozoglu N; Raspagliesi F; Buda A; Zanagnolo V; Zapardiel I; Jagasia N; Giuntoli R; Glickman A; Peiretti M; Lanner M; Chacon E; Di Guilmi J; Pereira A; Laas E; Fishman A; Nitschmann CC; Parker S; Joehlin-Price A; Lees B; Covens A; De Brot L; Taskiran C; Bogani G; Paniga C; Multinu F; Hernandez-Gutierrez A; Weaver AL; McGree ME; Mariani A
    Gynecol Oncol; 2021 Sep; 162(3):590-598. PubMed ID: 34274133
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preoperative cancer antigen-125 levels as a predictor of recurrence in early-stage endometrial cancer.
    Erturk A; Korkmaz E; Arslantas Z; Bekdemir S; Erturk NK
    Rev Assoc Med Bras (1992); 2024; 70(5):e20231115. PubMed ID: 38775501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.